Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study

Abstract

Acetaminophen ER 3900 mg/d administered for up to 12 weeks was effective in treating moderate to moderately severe chronic OA pain of the hip or knee and was generally well tolerated.

Abnormal Quantitative Sensory Testing is Associated With Persistent Pain One Year After TKA

“…2). When percentage change in WOMAC from preoperative to test day score was evaluated, patients with no pain postoperatively showed an improvement across all subscores of 77.1% to 79.3% (Table 2), a result that compares favorably with pharmacologic studies, which report improvements in total WOMAC ranging from 36% to 45% [1,3,6,21]. In contrast, the moderate-to-severe pain group showed improvement only across all subscores of 40.4% to 46.4%, suggesting that this is a distinct group for whom removal of diseased tissue provides an incomplete solution.…”

Supra-spinal FAAH is required for the analgesic action of paracetamol in an inflammatory context

“…However, these studies were conducted in naive animals. In the clinical setting, paracetamol is used in a pathological pain context, notably in nociceptive pain (Altman et al, 2007;Abbreviations: AM404, N-(4-Hydroxyphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide; DMSO, dimethyl sulfoxide; FAAH, fatty acid amide hydrolase; i.c.v., intracerebroventricular; i.p., intraperitoneal; i.pl., intra-plantar; PCR, polymerase chain reaction; PMSF, phenylmethylsulfonyl fluoride; p.o., per os; PWR, paw withdrawal responses; URB537, 3 0 -carbamoyl-biphenyl-3-yl-cyclohexylcarbamate; URB937, 3 0 -carbamoyl-6-hydroxy-[1,1 0 -biphenyl]-3-ylcyclohexylcarbamate. Wegman et al, 2004).…”

A randomized, double-blind, placebo-controlled 12 week trial of acetaminophen extended release for the treatment of signs and symptoms of osteoarthritis

“…The primary efficacy results of this study were consistent with a similarly conducted placebo-controlled osteoarthritis study of acetaminophen ER 3900 mg/day 23 in which the same three primary efficacy endpoints were evaluated. Acetaminophen ER 3900 mg/day was reported to be statistically significantly superior to placebo, when adjusted for investigator site and baseline covariates, for LS mean change from baseline through week 12 for the WOMAC pain subscale score (À25.9 vs À19.8, P ¼ 0.012), LS mean change from baseline through week 12 for the WOMAC physical function subscale score (À24.2 vs À18.2, P ¼ 0.016), and LS mean patient's global assessment of the response to therapy (2.11 vs 1.81, P ¼ 0.015) 23 . In addition, acetaminophen ER has been demonstrated in randomized, active-controlled, osteoarthritis clinical trials to be as effective as celecoxib 200 mg/ day and 400 mg/day through 2 weeks 24 , as effective as rofecoxib 12.5 mg/day through 4 weeks 25 , and as effective was naproxen 1000 mg/day through 8 weeks 26 .…”